Recombinant FIXFc: A novel therapy for the royal disease?

Expert Opinion on Biological Therapy

Volumn 11, Issue 10, 2011, Pages 1361-1368

  Valentino, Leonard A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Factor IX; Fragment crystallizable fusion proteins; Hemophilia B; Prophylaxis

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA B; HUMAN; NONHUMAN; PHARMACODYNAMICS; PROPHYLAXIS;

ANIMALS; FACTOR IX; HEMOPHILIA B; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

EID: 80052446216     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.603304     Document Type: Article

References (59)

1. Rogaev EI, Grigorenko AP, Moliaka YK, et al. Genomic identification in the historical case of the Nicholas II royal family. Proc Natl Acad Sci USA 2009;11:5258-63
2. Srivastava A, Giangrande P, Poon MC, et al. Guidelines for the management of hemophilia. Montreal, Quebec, Canada: World Federation of Hemophilia. Available from: www.wfh.org/2/docs/ ... and-Treatment/Guidelines-Mng-Hemophilia. pdf
3. Katz J. Prevalence of FIX inhibitors among patients with hemophilia B: results of a large scale North American survey. Haemophilia 1996;2:28-31 (Pubitemid 26056261)
4. White GC, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85(3):560-76
5. Pergantou H, Matsinos G, Papadopoulos A, et al. Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children. Haemophilia 2006;12:241-7
6. Gilbert MS. Musculoskeletal complications of haemophilia: the joint. Haemophilia 2000;6(Suppl):134-7
7. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12(Suppl):3117-21
8. Fuchs HE, Trapp HG, Griffith MJ, et al. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984;73:1696-703 (Pubitemid 14084486)
9. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998;35(2 Suppl 2):11-17 (Pubitemid 28177995)
10. Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998;35(2 Suppl 2):4-10 (Pubitemid 28177994)
11. Monahan PE, Di Paola J. Recombinant factor IX for clinical and research use. Semin Thromb Hemost 2010;36:498-509
12. Schaub R, Garzone P, Bouchard P, et al. Preclinical studies of recombinant factor IX. Semin Hematol 1998;35(2 Suppl 2):28-32 (Pubitemid 28177998)
13. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998;35(2 Suppl 2):33-8 (Pubitemid 28177999)
14. White GC II, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78(1):261-5 (Pubitemid 27289251)
15. Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004;10:629-48 (Pubitemid 39317773)
16. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004;10:134-46 (Pubitemid 38312640)
17. Santagostino E, Gringeri A, Berardinelli L, et al. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003;123:502-6 (Pubitemid 37363495)
18. McCarthy WJ, Valentino LA, Bonilla AS, et al. Arteriovenous fistula for long-term venous access for boys with hemophilia. J Vasc Surg 2007;45:986-90.discussion 990-991
19. National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). New York, NY: National Hemophilia Foundation, 2007. Available from: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid= 1007 Adopted November 4, 2007 [Last accessed 5 July 2011]
20. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32
21. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness ofprophylaxis in severe haemophilia. Haemophilia 2003;9:272-8 (Pubitemid 36622028)
22. Morfini M, Mannucci PM, Mariani G, et al.Mandelli F. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976;16:41-7
23. Poon MC, Aledort LM, Anderle K, et al. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995;35:319-23
24. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001;98:3600-6
25. Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006;12:75-81
26. Khair K, Lawrence K, Butler R, et al. Assessment of treatment practice patterns for severe hemophilia a: a global nurse perspective. Acta Haematol 2008;119:115-23 (Pubitemid 351591414)
27. Summary report of UDC national activity. Treatment/clinical characteristics (hemophilia). Atlanta, GA: Centers for Disease Control and Prevention 2011. Available from: https://www2a.cdc.gov/ncbddd/htcweb/UDC-Report/ UDC-Report.asp [Last accessed 5 July 2011]
28. Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337:525-31 (Pubitemid 19045536)
29. Ashkenazi A, Capon DJ, Ward RH. Immunoadhesins. Int Rev Immunol 1993;10:219-27
30. Korhonen R, Moilanen E. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2010;106:13-21
31. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101:9763-8 (Pubitemid 38869310)
32. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010;115:2057-64
33. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25 (Pubitemid 47327396)
34. Borvak J, Richardson J, Medesan C, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol 1998;10:1289-98 (Pubitemid 28414334)
35. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol 2000;18739-66
36. Israel EJ, Simister N, Freiberg E, et al. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology 1993;79:77-81 (Pubitemid 23151196)
37. Nawroth PP, McCarthy D, Kisiel W, et al. Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells. J Exp Med 1985;162:559-72 (Pubitemid 15249959)
38. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006;20:151-60 (Pubitemid 43845335)
39. Kim JK, Firan M, Radu CG, et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999;29:2819-25 (Pubitemid 30099006)
40. Chinen J, Shearer WT. Advances in basic and clinical immunology in 2010. J Allergy Clin Immunol 2011;127:336-41
41. Kaveri SV, Maddur MS, Hegde P, et al. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011;164(Suppl):22-5
42. Jovanovic V, Dai X, Lim YT, et al. Fcgamma receptor biology and systemic lupus erythematosus. Int J Rheum Dis 2009;12:293-8
43. Sabatino B, Van Liew JB. The renal handling of IgG in the aging rat and in experimental kidney disease. Proc Soc Exp Biol Med 1997;216:414-23
44. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010;30(Suppl 1):S9-14
45. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008;20:471-8
46. Arend SP, Webster DE. Catabolism and biologic properties of two species of rat IgG2a Fc fragments. J Immunol 1977;118:395-400 (Pubitemid 8053056)
47. Dumont JA. Monomeric Fc fusion moledules. In: An Z. editor. Therapeutic monoclonal antibodies. From bench to clinic. John Wiley & Sons, Inc; New York, NY; 2009. p. 779-96
48. Shapiro AD, Ragni M, Valentino L, et al. Safety and prolonged biological activity following a single administration of a recombinant molecular fusion of native human coagulation factor FIX and the Fc region of immunoglobulin G (IGg) (rFIXFc) to subjects with hemophilia B. Haemophilia 2010;16(Suppl 4):abstract 07FPO07
49. BeneFIX Coagulation Factor IX (Recombinant) [package insert]. Wyeth Pharmaceuticals, Inc., Philadelphia, PA; 2010
50. Biogen Idec. Study of recombinant factor IX Fc fusion protein (rFIXFc) in subjectswith hemophilia B ClinicalTrials.gov NCT01027364 Available from: http:// www.clinicaltrials.gov/ct2/results ? term=NCT01027364 [Accessed 21 February 2011]
51. Schulman S, Eelde A, Holmstrom M, et al. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008;6:1113-21 (Pubitemid 351859120)
52. Lowe GD, Ludlam CA. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost 2008;6:1982-3
53. Hacker MR, Geraghty S,Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001;7:392-6 (Pubitemid 32677658)
54. Bohn RL, Aledort LM, Putnam KG, et al. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004;10:63-8 (Pubitemid 38195627)
55. Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs 2010;15:597-613
56. Micheloud D, Nuno L, Rodriguez-Mahou M, et al. Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 2006;15:881-5 (Pubitemid 46044921)
57. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007;46:695-8 (Pubitemid 46523319)
58. Scioscia C, Scioscia M, Anelli MG, et al. Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis. Clin Exp Rheumatol 2011;29:93-5
59. Umeda N, Ito S, Hayashi T, et al. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med 2010;49:187-9